Dopaminergic and glutamatergic dysfunctions in the neuropathophysiology of schizophrenia

Dopamine: Functions, Regulation and Health Effects

Volumn , Issue , 2012, Pages 169-194

  Gao, Wen Jun ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine; Glutamate; NMDA receptors; Prefrontal cortex; Psychiatric disorders; Schizophrenia

Indexed keywords

EID: 84892040004     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (224)

1. Seeman, P., Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987. 1(2): p. 133-52.
2. Meltzer, H.Y. and S.M. Stahl, The Dopamine Hypothesis of Schizophrenia: A Review*. Schizophrenia Bulletin, 1976. 2(1): p. 19-76.
3. Carlsson, A. and M. Lindqvist, Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica, 1963. 20: p. 140-4.
4. Creese, I., D.R. Burt, and S.H. Snyder, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 1976. 192(4238): p. 481-3.
5. Seeman, P., et al., Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A, 1975. 72(11): p. 4376-80.
6. Dreyer, J.L., Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Molecular Biotechnology, 2011. 47(2): p. 169-87.
7. Davis, K.L., et al., Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry, 1991. 148(11): p. 1474-86.
8. Howes, O.D. and S. Kapur, The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull, 2009. 35(3): p. 549-62.
9. Lieberman, J.A., J.M. Kane, and J. Alvir, Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl), 1987. 91(4): p. 415-33.
10. Reynolds, G.P., Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br J Psychiatry, 1989. 155: p. 305-16.
11. Kapur, S. and G. Remington, Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry, 2001. 50(11): p. 873-83.
12. Tauscher, J., et al., Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry, 2004. 161(9): p. 1620-5.
13. Lieberman, J.A., J.M. Kane, and C.A. Johns, Clozapine: guidelines for clinical management. J Clin Psychiatry, 1989. 50(9): p. 329-38.
14. Harrison, P.J. and D.R. Weinberger, Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry, 2005. 10(1): p. 40-68.
15. Goldman-Rakic, P.S., et al., Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl), 2004. 174(1): p. 3-16.
16. Simpson, E.H., C. Kellendonk, and E. Kandel, A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron, 2010. 65(5): p. 585-596.
17. Goldman-Rakic, P.S., E.C. Muly, 3rd, and G.V. Williams, D(1) receptors in prefrontal cells and circuits. Brain Res Rev, 2000. 31(2-3): p. 295-301.
18. Abi-Dargham, A., et al., Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci, 2002. 22(9): p. 3708-19.
19. Abi-Dargham, A. and H. Moore, Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist, 2003. 9(5): p. 404-16.
20. Tamminga, C.A., The neurobiology of cognition in schizophrenia. J Clin Psychiatry, 2006. 67 Suppl 9: p. 9-13; discussion 36-42.
21. Okubo, Y., et al., Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 1997. 385(6617): p. 634-6.
22. Knable, M.B. and D.R. Weinberger, Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol, 1997. 11(2): p. 123-31.
23. Pycock, C.J., R.W. Kerwin, and C.J. Carter, Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature, 1980. 286(5768): p. 74-6.
24. Tzschentke, T.M., Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol, 2001. 63(3): p. 241-320.
25. Karreman, M. and B. Moghaddam, The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem, 1996. 66(2): p. 589-98.
26. Kolachana, B.S., R.C. Saunders, and D.R. Weinberger, Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience, 1995. 69(3): p. 859-68.
27. Wilkinson, L.S., The nature of interactions involving prefrontal and striatal dopamine systems. J Psychopharmacol, 1997. 11(2): p. 143-50.
28. Weinberger, D.R. and K.F. Berman, Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull, 1988. 14(2): p. 157-68.
29. Weinberger, D.R., Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry, 1987. 44(7): p. 660-9.
30. Grace, A.A., Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology, 2011.
31. Davidson, L.L. and R.W. Heinrichs, Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Research, 2003. 122(2): p. 69-87.
32. McGuire, P., et al., Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci, 2008. 29(2): p. 91-8.
33. Meyer-Lindenberg, A., et al., Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci, 2002. 5(3): p. 267-71.
34. Hietala, J., et al., Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res, 1999. 35(1): p. 41-50.
35. Hietala, J., et al., Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet, 1995. 346(8983): p. 1130-1.
36. McGowan, S., et al., Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry, 2004. 61(2): p. 134-42.
37. Lindstrom, L.H., et al., Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry, 1999. 46(5): p. 681-8.
38. Howes, O.D., et al., Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry, 2009. 66(1): p. 13-20.
39. Howes, O.D., et al., Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. British Journal of Psychiatry. Supplement, 2007. 51: p. s13-8.
40. Reith, J., et al., Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A, 1994. 91(24): p. 11651-4.
41. Laruelle, M., et al., Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse, 1997. 25(1): p. 1-14.
42. Laruelle, M., Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of Cerebral Blood Flow and Metabolism, 2000. 20(3): p. 423-51.
43. Abi-Dargham, A., et al., Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry, 1998. 155(6): p. 761-7.
44. Breier, A., et al., Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A, 1997. 94(6): p. 2569-74.
45. Laruelle, M., et al., Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A, 1996. 93(17): p. 9235-40.
46. Laruelle, M. and A. Abi-Dargham, Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol, 1999. 13(4): p. 358-71.
47. Abi-Dargham, A., et al., Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A, 2000. 97(14): p. 8104-9.
48. Gjedde, A. and D.F. Wong, Positron tomographic quantitation of neuroreceptors in human brain in vivo--with special reference to the D2 dopamine receptors in caudate nucleus. Neurosurgical Review, 1987. 10(1): p. 9-18.
49. Wong, D.F., et al., Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science, 1986. 234(4783): p. 1558-63.
50. Crawley, J.C., et al., Uptake of 77Br-spiperone in the striata of schizophrenic patients and controls. Nuclear Medicine Communications, 1986. 7(8): p. 599-607.
51. Martinot, J.L., et al., Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry, 1990. 147(1): p. 44-50.
52. Farde, L., et al., D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry, 1990. 47(3): p. 213-9.
53. Suhara, T., et al., Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry, 2002. 59(1): p. 25-30.
54. Buchsbaum, M.S., et al., D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res, 2006. 85(1-3): p. 232-44.
55. Talvik, M., et al., Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Research, 2006. 148(2-3): p. 165-73.
56. Takahashi, H., M. Higuchi, and T. Suhara, The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry, 2006. 59(10): p. 919-28.
57. Seeman, P., All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther, 2011. 17(2): p. 118-32.
58. Seeman, P., Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Therap Targets, 2006. 10(4): p. 515-531.
59. Seeman, P., et al., Psychosis pathways converge via D2high dopamine receptors. Synapse, 2006. 60(4): p. 319-46.
60. Seeman, P., et al., Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A, 2005. 102(9): p. 3513-8.
61. Graff-Guerrero, A., et al., The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology, 2009. 34(4): p. 1078-86.
62. Patil, S.T., et al., Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med, 2007. 13(9): p. 1102-1107.
63. Weinberger, D.R., Schizophrenia drug says goodbye to dopamine. Nat Med, 2007. 13(9): p. 1018-1019.
64. Allen, N.C., et al., Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet, 2008. 40(7): p. 827-34.
65. Tan, H.Y., J.H. Callicott, and D.R. Weinberger, Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cogn Neuropsychiatry, 2009. 14(4-5): p. 277-98.
66. Tunbridge, E.M., P.J. Harrison, and D.R. Weinberger, Catechol-o-Methyltransferase, cognition, and psychosis: Val158Met and beyond. Biological Psychiatry, 2006. 60(2): p. 141-151.
67. Savitz, J., M. Solms, and R. Ramesar, The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav, 2006. 5(4): p. 311-28.
68. Cannon, T.D., The inheritance of intermediate phenotypes for schizophrenia. Curr Opin Psychiatry, 2005. 18(2): p. 135-40.
69. Bilder, R.M., et al., The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 2004. 29(11): p. 1943-61.
70. Weinberger, D.R., et al., Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry, 2001. 50(11): p. 825-44.
71. Kato, T., et al., Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol Psychiatry, 2011. 16(3): p. 307-320.
72. Roy, K., et al., Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. PNAS, 2007. 104(19): p. 8131-8136.
73. Niwa, M., et al., Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron, 2010. 65(4): p. 480-9.
74. Lipina, T.V., et al., Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav, 2010. 9(7): p. 777-89.
75. Ji, Y., et al., Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proceedings of the National Academy of Sciences, 2009. 106(46): p. 19593-19598.
76. Papaleo, F. and D.R. Weinberger, Dysbindin and Schizophrenia: it's dopamine and glutamate all over again. Biol Psychiatry, 2011. 69(1): p. 2-4.
77. Iizuka, Y., et al., Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J. Neurosci., 2007. 27(45): p. 12390-12395.
78. Papaleo, F., B.K. Lipska, and D.R. Weinberger, Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology, 2011.
79. Shi, J., E.S. Gershon, and C. Liu, Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr Res, 2008. 104(1-3): p. 96-107.
80. Hahn, C.G., et al., Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med, 2006. 12(7): p. 824-8.
81. Guidotti, A., et al., Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology, 2011. 60(7-8): p. 1007-1016.
82. Kundakovic, M., et al., The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol, 2009. 75(2): p. 342-54.
83. Guidotti, A., et al., Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci, 2009. 30(2): p. 55-60.
84. Stefansson, H., et al., Large recurrent microdeletions associated with schizophrenia. Nature, 2008. 455(7210): p. 232-6.
85. O'Donovan, M.C., et al., Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet, 2008. 40(9): p. 1053-5.
86. Talkowski, M.E., et al., A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet, 2008. 17(5): p. 747-58.
87. Cantor-Graae, E., The contribution of social factors to the development of schizophrenia: a review of recent findings. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 2007. 52(5): p. 277-86.
88. van Winkel, R., N.C. Stefanis, and I. Myin-Germeys, Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull, 2008. 34(6): p. 1095-105.
89. Brown, A.S., The environment and susceptibility to schizophrenia. Prog Neurobiol, 2010.
90. Morgan, D., et al., Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci, 2002. 5(2): p. 169-74.
91. Hall, F.S., et al., Maternal deprivation of neonatal rats produces enduring changes in dopamine function. Synapse, 1999. 32(1): p. 37-43.
92. Hall, F.S., et al., Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol Biochem Behav, 1998. 59(4): p. 859-72.
93. Tidey, J.W. and K.A. Miczek, Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res, 1996. 721(1-2): p. 140-9.
94. Cannon, M., P.B. Jones, and R.M. Murray, Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry, 2002. 159(7): p. 1080-92.
95. Geddes, J.R. and S.M. Lawrie, Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry, 1995. 167(6): p. 786-93.
96. Kunugi, H., S. Nanko, and R.M. Murray, Obstetric complications and schizophrenia: prenatal underdevelopment and subsequent neurodevelopmental impairment. British Journal of Psychiatry. Supplement, 2001. 40: p. s25-9.
97. Boksa, P., Animal models of obstetric complications in relation to schizophrenia. Brain Res Brain Res Rev, 2004. 45(1): p. 1-17.
98. Boksa, P. and B.F. El-Khodor, Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci Biobehav Rev, 2003. 27(1-2): p. 91-101.
99. Lodge, D.J. and A.A. Grace, Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res, 2009. 204(2): p. 306-12.
100. Lipska, B.K., et al., Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology, 2002. 27(1): p. 47-54.
101. Lipska, B.K., et al., Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat. J Neurosci, 2002. 22(7): p. 2835-42.
102. Lipska, B.K., G.E. Jaskiw, and D.R. Weinberger, Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology, 1993. 9(1): p. 67-75.
103. Diaz, R., et al., Prenatal corticosterone increases spontaneous and d-amphetamine induced locomotor activity and brain dopamine metabolism in prepubertal male and female rats. Neuroscience, 1995. 66(2): p. 467-73.
104. Flores, G., et al., Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex. J Neurosci, 1996. 16(22): p. 7366-75.
105. O'Donnell, P., Adolescent maturation of cortical dopamine. Neurotox Res, 2010. 18(3-4): p. 306-12.
106. Feleder, C., et al., Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats. Biol Psychiatry, 2010. 67(4): p. 386-92.
107. Tseng, K.Y., et al., Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biol Psychiatry, 2007. 62(7): p. 730-8.
108. Gruber, A.J., et al., More is less: a disinhibited prefrontal cortex impairs cognitive flexibility. J. Neurosci., 2010. 30(50): p. 17102-17110.
109. Fortier, M.E., et al., Maternal exposure to bacterial endotoxin during pregnancy enhances amphetamine-induced locomotion and startle responses in adult rat offspring. J Psychiatr Res, 2004. 38(3): p. 335-45.
110. Watanabe, M., et al., Effects of prenatal methylazoxymethanol treatment on striatal dopaminergic systems in rat brain. Neurosci Res, 1998. 30(2): p. 135-44.
111. Kehoe, P., et al., Brain dopamine response in isolated 10-day-old rats: assessment using D2 binding and dopamine turnover. Pharmacol Biochem Behav, 1996. 53(1): p. 41-9.
112. Kehoe, P., et al., Repeated isolation in the neonatal rat produces alterations in behavior and ventral striatal dopamine release in the juvenile after amphetamine challenge. Behav Neurosci, 1996. 110(6): p. 1435-44.
113. Bossong, M.G. and R.J.M. Niesink, Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology, 2010. 92(3): p. 370-385.
114. Boileau, I., et al., Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry, 2006. 63(12): p. 1386-95.
115. Arseneault, L., et al., Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry, 2004. 184: p. 110-7.
116. Moore, T.H., et al., Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007. 370(9584): p. 319-28.
117. Laviolette, S.R. and A.A. Grace, The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci, 2006. 63(14): p. 1597-613.
118. Vinod, K.Y. and B.L. Hungund, Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opin Ther Targets, 2006. 10(2): p. 203-10.
119. Freund, T.F., I. Katona, and D. Piomelli, Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 2003. 83: p. 1017-1066.
120. Cheer, J.F., et al., Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci, 2004. 24(18): p. 4393-400.
121. Kegeles, L.S., et al., Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry, 2000. 48(7): p. 627-40.
122. Mount, H., et al., Phencyclidine and related compounds evoked [3H]dopamine release from rat mesencephalic cell cultures by a mechanism independent of the phencyclidine receptor, sigma binding site, or dopamine uptake site. Can J Physiol Pharmacol, 1990. 68(9): p. 1200-6.
123. Hondo, H., et al., Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res, 1994. 633(1-2): p. 337-42.
124. Schmidt, C.J. and G.M. Fadayel, Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther, 1996. 277(3): p. 1541-9.
125. Jentsch, J.D., et al., Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berl), 1998. 138(1): p. 89-95.
126. Jaaro-Peled, H., et al., Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends in Neurosciences, 2009. 32(9): p. 485-495.
127. Lewis, D.A. and G. Gonzalez-Burgos, Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacol, 2008. 33(1): p. 141-65.
128. Walsh, T., et al., Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science, 2008. 320(5875): p. 539-43.
129. Costa, E., et al., Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv Pharmacol, 2006. 54: p. 95-117.
130. Crow, T.J., How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry, 2007. 164(1): p. 13-21.
131. Insel, T.R., Rethinking schizophrenia. Nature, 2010. 468(7321): p. 187-193.
132. Lieberman, J.A., L.F. Jarskog, and D. Malaspina, Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J Clin Psychiatry, 2006. 67(6): p. 983-90.
133. Lencz, T., B. Cornblatt, and R.M. Bilder, Neurodevelopmental models of schizophrenia: pathophysiologic synthesis and directions for intervention research. Psychopharmacol Bull, 2001. 35(1): p. 95-125.
134. Tenn, C.C., P.J. Fletcher, and S. Kapur, A putative animal model of the "prodromal" state of schizophrenia. Biol Psychiatry, 2005. 57(6): p. 586-93.
135. Cannon, T.D., et al., Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry, 2008. 65(1): p. 28-37.
136. Soliman, A., et al., Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study. Neuropsychopharmacology, 2008. 33(8): p. 2033-41.
137. Brunelin, J., et al., Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr Res, 2008. 100(1-3): p. 206-11.
138. Myin-Germeys, I., et al., Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry, 2005. 58(2): p. 105-10.
139. Nicodemus, K.K., et al., Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry, 2008. 13(9): p. 873-7.
140. Cannon, T.D., et al., Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry, 2002. 59(1): p. 35-41.
141. van Os, J., B.P. Rutten, and R. Poulton, Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull, 2008. 34(6): p. 1066-82.
142. Pruessner, J.C., et al., Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci, 2004. 24(11): p. 2825-31.
143. Howes, S.R., et al., Leftward shift in the acquisition of cocaine self-administration in isolation-reared rats: relationship to extracellular levels of dopamine, serotonin and glutamate in the nucleus accumbens and amygdala-striatal FOS expression. Psychopharmacology (Berl), 2000. 151(1): p. 55-63.
144. Fulford, A.J. and C.A. Marsden, Effect of isolation-rearing on conditioned dopamine release in vivo in the nucleus accumbens of the rat. J Neurochem, 1998. 70(1): p. 384-90.
145. Caspi, A., et al., Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry, 2005. 57(10): p. 1117-27.
146. Cantor-Graae, E. and J.P. Selten, Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry, 2005. 162(1): p. 12-24.
147. van Os, J., et al., Do urbanicity and familial liability coparticipate in causing psychosis? Am J Psychiatry, 2003. 160(3): p. 477-82.
148. Featherstone, R.E., et al., Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology, 2007. 32(2): p. 483-92.
149. Hoftman, G.D. and D.A. Lewis, Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia. Schizophr Bull, 2011. 37(3): p. 493-503.
150. Meyer, U. and J. Feldon, Epidemiology-driven neurodevelopmental animal models of schizophrenia. Progress in Neurobiology, 2010. 90(3): p. 285-326.
151. Hayashi-Takagi, A. and A. Sawa, Disturbed synaptic connectivity in schizophrenia: Convergence of genetic risk factors during neurodevelopment. Brain Research Bulletin, 2010. 83(3-4): p. 140-146.
152. Kellendonk, C., E.H. Simpson, and E.R. Kandel, Modeling cognitive endophenotypes of schizophrenia in mice. Trends in Neurosciences, 2009. 32(6): p. 347-358.
153. Kellendonk, C., et al., Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron, 2006. 49(4): p. 603-615.
154. Parker, J.G., et al., Absence of NMDA receptors in dopamine neurons attenuates dopamine release but not conditioned approach during Pavlovian conditioning. Proc Natl Acad Sci U S A, 2010. 107(30): p. 13491-6.
155. Zweifel, L.S., et al., Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron, 2008. 59(3): p. 486-496.
156. Lau, C.G. and R.S. Zukin, NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci, 2007. 8(6): p. 413-426.
157. Monyer, H., et al., Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron, 1994. 12(3): p. 529-40.
158. Sheng, M., et al., Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature, 1994. 368(6467): p. 144-7.
159. Quinlan, E.M., D.H. Olstein, and M.F. Bear, Bidirectional, experience-dependent regulation of N-methyl-D-aspartate receptor subunit composition in the rat visual cortex during postnatal development. Proc Natl Acad Sci U S A, 1999. 96(22): p. 12876-80.
160. Roberts, A.C., et al., Downregulation of NR3A-containing NMDARs is required for synapse maturation and memory consolidation. Neuron, 2009. 63(3): p. 342-356.
161. Dumas, T.C., Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative learning. Prog Neurobiol, 2005. 76(3): p. 189-211.
162. Henson, M.A., et al., Influence of the NR3A subunit on NMDA receptor functions. Progress in Neurobiology, 2010. 91(1): p. 23-37.
163. Spear, L.P., The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev, 2000. 24(4): p. 417-463.
164. Brenhouse, H.C., K.C. Sonntag, and S.L. Andersen, Transient D1 dopamine receptor expression on prefrontal cortex projection neurons: relationship to enhanced motivational salience of drug cues in adolescence. J. Neurosci., 2008. 28(10): p. 2375-2382.
165. Tang, Y.P., et al., Genetic enhancement of learning and memory in mice. Nature, 1999. 401(6748): p. 63-9.
166. Zhao, M.-G., et al., Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron, 2005. 47(6): p. 859-872.
167. Mohn, A.R., et al., Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell, 1999. 98(4): p. 427-36.
168. von Engelhardt, J., et al., Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron, 2008. 60(5): p. 846-860.
169. Dunah, A.W., et al., Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol, 2004. 65(1): p. 121-9.
170. Dunah, A.W. and D.G. Standaert, Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci, 2001. 21(15): p. 5546-58.
171. Hallett, P.J., et al., Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J. Neurosci., 2006. 26(17): p. 4690-4700.
172. Tong, H. and A.J. Gibb, Dopamine D1 receptor inhibition of NMDA receptor currents mediated by tyrosine kinase-dependent receptor trafficking in neonatal rat striatum. J Physiol, 2008. 586(19): p. 4693-4707.
173. Li, Y.C., et al., Dopamine D1 receptor-mediated enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic insertion in the prefrontal neurons. J Neurochem, 2010. 114: p. 62-73.
174. Hu, J.-L., et al., Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons. Molecular Brain 2010. 3(20): p. 1-14.
175. Groc, L., et al., NMDA receptor surface mobility depends on NR2A-2B subunits. Proc. Natl Acad. Sci. USA, 2006. 103(49): p. 18769-18774.
176. Lavezzari, G., et al., Subunit-specific regulation of NMDA receptor endocytosis. J Neurosci, 2004. 24(28): p. 6383-91.
177. Roche, K.W., et al., Molecular determinants of NMDA receptor internalization. Nat Neurosci, 2001. 4(8): p. 794-802.
178. Wang, H.X., et al., A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc. Nat. Acad. Sci. USA, 2008. 105(43): p. 16791-16796.
179. Li, Y.C., et al., Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci, 2009. 29(49): p. 15551-63.
180. Wei, F., et al., Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci, 2001. 4(2): p. 164-9.
181. Hardingham, G.E. and H. Bading, The Yin and Yang of NMDA receptor signalling. Trends Neurosci, 2003. 26(2): p. 81-89.
182. Liu, Y., et al., NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci., 2007. 27(11): p. 2846-2857.
183. Picconi, B., et al., NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke, 2006. 37(7): p. 1895-901.
184. De Souza Silva, M.A., et al., NR2C by NR2B subunit exchange in juvenile mice affects emotionality and 5-HT in the frontal cortex. Genes Brain Behav, 2007. 6(5): p. 465-72.
185. Lewis, D.A. and G. Gonzalez-Burgos, Pathophysiologically based treatment interventions in schizophrenia. Nat Med, 2006. 12(9): p. 1016-22.
186. Laruelle, M., et al., Mechanism of action of antipsychotic drugs: From dopamine D2 receptor antagonism to glutamate NMDA facilitation. Clinical Therapeutics, 2005. 27(Supplement 1): p. S16-S24.
187. Moghaddam, B. and M.E. Jackson, Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci, 2003. 1003: p. 131-7.
188. Javitt, D.C., Glutamate as a therapeutic target in psychiatric disorders. Molecular Psychiatry, 2004. 9(11): p. 984-97.
189. Millan, M.J., N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacol (Berl), 2005. 179(1): p. 30-53.
190. Coyle, J.T., Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology, 2006. 26(4-6): p. 365-384.
191. Tamminga, C., Glutamatergic aspects of schizophrenia. Br J Psychiatry Suppl, 1999(37): p. 12-5.
192. Olney, J.W., J.W. Newcomer, and N.B. Farber, NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research, 1999. 33(6): p. 523-533.
193. Dracheva, S., et al., N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. American Journal of Psychiatry, 2001. 158(9): p. 1400-1410.
194. Krystal, J.H., A. Anand, and B. Moghaddam, Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry, 2002. 59(7): p. 663-4.
195. Javitt, D.C. and S.R. Zukin, Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 1991. 148(10): p. 1301-8.
196. Krystal, J.H., et al., Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archive General Psychiatry, 1994. 51(3): p. 199-214.
197. Lahti, A.C., et al., Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol, 1995. 13(1): p. 9-19.
198. Moghaddam, B., Bringing order to the glutamate chaos in schizophrenia. Neuron, 2003. 40(5): p. 881-84.
199. Kristiansen, L.V., et al., NMDA receptors and schizophrenia. Current Opinion of Pharmacology, 2007. 7(1): p. 48-55.
200. Akbarian, S., et al., Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci, 1996. 16(1): p. 19-30.
201. Gao, X.M., et al., Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry, 2000. 157(7): p. 1141-9.
202. Lisman, J.E., et al., Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 2008. 31(5): p. 234-242.
203. Gunduz-Bruce, H., The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev, 2009. 60(2): p. 279-86.
204. Clinton, S.M. and J.H. Meador-Woodruff, Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacol, 2004. 29(7): p. 1353-62.
205. Lewis, D.A., T. Hashimoto, and D.W. Volk, Cortical inhibitory neurons and schizophrenia. Nature Rev Neurosci, 2005. 6(4): p. 312-24.
206. Olney, J.W. and N.B. Farber, Glutamate receptor dysfunction and schizophrenia. Archive General Psychiatry, 1995. 52(12): p. 998-1007.
207. Lindsley, C.W., et al., Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem, 2006. 6(8): p. 771-85.
208. Morris, B.J., S.M. Cochran, and J.A. Pratt, PCP: from pharmacology to modelling schizophrenia. Current Opinion of Pharmacology, 2005. 5(1): p. 101-6.
209. Grimwood, S., et al., NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport, 1999. 10(3): p. 461-5.
210. Clinton, S.M., et al., Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry, 2003. 160(6): p. 1100-9.
211. Goff, D.C. and L. Wine, Glutamate in schizophrenia: clinical and research implications. Schizophr Res, 1997. 27(2-3): p. 157-68.
212. Eastwood, S.L., R.W. Kerwin, and P.J. Harrison, Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry, 1997. 41(6): p. 636-43.
213. Coyle, J.T. and G. Tsai, The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacol, 2004. 174(1): p. 32-38.
214. Dwivedi, Y., et al., ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol Psychiatry, 2005. 11(1): p. 86-98.
215. Wang, H.X. and W.J. Gao, Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacol, 2009. 34(8): p. 2028-40.
216. Seeman, P. and T. Lee, Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science, 1975. 188(4194): p. 1217-9.
217. Akil, M., et al., Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry, 1999. 156(10): p. 1580-9.
218. Abi-Dargham, A., Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol, 2004. 7 Suppl 1: p. S1-5.
219. Goldman-Rakic, P.S., Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci, 1994. 6(4): p. 348-57.
220. Benes, F.M., et al., Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Archive General Psychiatry, 1991. 48(11): p. 996-1001.
221. Beasley, C.L. and G.P. Reynolds, Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research, 1997. 24(3): p. 349-55.
222. Lewis, D.A., et al., Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry, 1999. 46(5): p. 616-26.
223. Li, Y.-C., et al., D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortex. Proceedings of the National Academy of Sciences, 2011. 108(29): p. 12107-12112.
224. Abi-Dargham, A., Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? World Psychiatry, 2003. 2(3): p. 166-71.